Connect Biopharma Holdings Ltd. has announced plans to terminate its American Depositary Receipt $(ADR.AU)$ program and directly list its ordinary shares on the Nasdaq Global Market. The transition will involve exchanging ADRs for ordinary shares at a one-for-one ratio. The company's ordinary shares will trade on Nasdaq under the symbol "CNTB" following the expected termination of the ADR program on or about September 2, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497136-en) on July 21, 2025, and is solely responsible for the information contained therein.